Torna al Registre Simple

 
dc.contributorDepartament de Salut
dc.contributor.authorSanvisens, Arantza
dc.contributor.authorRivas, Inmaculada
dc.contributor.authorFaure, Eva
dc.contributor.authorEspinach Garcia, Nestor
dc.contributor.authorHernandez-Rubio, Anna
dc.contributor.authorMajó-Roca, Xavier
dc.contributor.authorColom-Farran, Joan
dc.contributor.authorMuga, Robert
dc.date.accessioned2022-02-07T12:12:03Z
dc.date.available2022-02-07T12:12:03Z
dc.date.issued2020-10-14
dc.identifier.citationSanvisens A, Rivas I, Faure E, Espinach N, Hernandez-Rubio, A, Majó X, et al. Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. World J Gastroenterol. 2020 Oct 14;26(38):5874-5883.
dc.identifier.issn1007-9327
dc.identifier.urihttp://hdl.handle.net/11351/6983
dc.descriptionAgents antivirals d'acció directa; Programa de tractament amb opioides; Teràpia amb agonistes opioides; Infecció pel virus de l'hepatitis C; Infecció pel virus de la immunodeficiència humana; Ús de drogues
dc.description.sponsorshipSupported by the Ministry of Science, Innovation and Universities, Carlos III Health Institute (ISCIII), European Fund for Regional Development (FEDER), Network for Cooperative Research in Health (RETICS), Spain (No. RD16/0017/0003, PI17/00174, INT19/00026, CD19/00019); the Ministry of Health, National Plan on Drugs (PNSD), Spain (No. 2018/020); the European Commission (806996- JUSTSO-JUST2017-AG-DRUG); the Gilead Fellowship Program, Gilead Sciences (No. GLD17/187); the Ministry of Education, Spain (No. PRX18/00245); the Agency for Management of University and Research Grants, Government of Catalonia (No. 2017SGR316); and the Municipal Institute of Personal Services-IMSP, Badalona.
dc.language.isoeng
dc.publisherBaishideng Publishing Group
dc.relation.ispartofseriesWorld journal of gastroenterology;26(38)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectInfeccions per VIH - Tractament
dc.subjectVirus de l'hepatitis C - Tractament
dc.subjectOpiacis - Ús terapèutic
dc.subject.meshHIV Infections
dc.subject.meshOpiate Substitution Treatment
dc.subject.meshHepatitis C
dc.titleMonitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3748/wjg.v26.i38.5874
dc.subject.decsinfecciones por VIH
dc.subject.decstratamiento de sustitución de opiaceos
dc.subject.decshepatitis C
dc.relation.publishversionhttp://dx.doi.org/10.3748/wjg.v26.i38.5874
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Sanvisens A] Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Rivas I, Faure E, Espinach N] Mental Health and Addiction Service, Badalona Serveis Assistencials-BSA, Badalona, Spain. [Hernandez-Rubio A, Muga R] Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. [Majó X, Colom J] Programa de Prevenció, Control i Atenció al VIH, les MTS i les Hepatitis Víriques, Agència de Salut Pública de Catalunya (ASPCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain
dc.identifier.pmid33132641
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple